Invivyd (NASDAQ:IVVD) Receives "Buy" Rating from D. Boral Capital

Invivyd (NASDAQ:IVVD - Get Free Report)'s stock had its "buy" rating restated by investment analysts at D. Boral Capital in a research report issued on Wednesday,Benzinga reports. They presently have a $9.00 target price on the stock.

A number of other equities research analysts have also recently commented on the company. Morgan Stanley decreased their price objective on Invivyd from $9.50 to $3.55 and set an "overweight" rating for the company in a research note on Wednesday, November 20th. HC Wainwright reaffirmed a "buy" rating and set a $10.00 price objective on shares of Invivyd in a research note on Monday, February 24th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $7.89.

Invivyd Price Performance

Shares of IVVD stock traded down $0.02 on Wednesday, reaching $1.01. 1,341,351 shares of the stock were exchanged, compared to its average volume of 20,580,926. The stock has a market cap of $120.81 million, a PE ratio of -0.52 and a beta of 0.09. Invivyd has a one year low of $0.35 and a one year high of $4.74. The stock has a 50 day moving average price of $0.92 and a 200 day moving average price of $0.88.

Insider Buying and Selling at Invivyd

In other news, Director Terrance Mcguire sold 150,000 shares of the business's stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $0.61, for a total value of $91,500.00. Following the sale, the director now directly owns 4,538,079 shares in the company, valued at $2,768,228.19. The trade was a 3.20 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last ninety days, insiders sold 816,466 shares of company stock valued at $423,214. Company insiders own 17.90% of the company's stock.

Remove Ads

Institutional Trading of Invivyd

A number of institutional investors have recently modified their holdings of IVVD. Proficio Capital Partners LLC bought a new stake in Invivyd during the third quarter worth about $27,000. Jane Street Group LLC raised its holdings in Invivyd by 290.5% during the fourth quarter. Jane Street Group LLC now owns 117,432 shares of the company's stock worth $52,000 after acquiring an additional 87,358 shares in the last quarter. Barclays PLC raised its holdings in Invivyd by 7.8% during the fourth quarter. Barclays PLC now owns 127,180 shares of the company's stock worth $56,000 after acquiring an additional 9,207 shares in the last quarter. Renaissance Technologies LLC bought a new stake in Invivyd during the fourth quarter worth about $74,000. Finally, JPMorgan Chase & Co. raised its holdings in Invivyd by 644.1% during the fourth quarter. JPMorgan Chase & Co. now owns 256,900 shares of the company's stock worth $114,000 after acquiring an additional 222,375 shares in the last quarter. 70.36% of the stock is currently owned by institutional investors.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.